Roche's Genentech division has formed an ... upfront to license rights to off-the-shelf CAR-T therapies from Poseida Therapeutics aimed at haematological cancers, including one targeting BCMA ...

While not discussed at ACR 2024, Roche’s recent acquisition of Poseida Therapeutics adds another layer of optimism to the cell therapy landscape. Poseida’s gene-editing and cell therapy ...

Roche (OTCQX:RHHBY) has received FDA clearance with a CLIA waiver for its cobas liat sexually transmitted infection, or STI, multiplex assay panels. The tests will be available exclusively in the U.S.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Structure Therapeutics Inc. is not currently rated by Sustainalytics. Combining insights from the ESG Risk Rating and Morningstar Equity Research, we find that Pfizer and Roche stand out as ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF230.00. The company’s shares closed last Friday at ...

A Cape Coral man was found guilty of racketeering in a series of real estate scams by targeting victims through presentations in Haitian churches and on a Creole radio station to the tune of ...

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...